← back to search

Alexandra G. Lopez‐Aguiar

University of Miami · US
Area of research
Oncology · Epidemiology
Research interest
Research interests include Neuroendocrine Tumor Research Advances, Pancreatic and Hepatic Oncology Research, Lung Cancer Research Studies, and Ubiquitin and proteasome pathways.
h-index
24
citations
1,669
works
128
NIH funding
primary concept
email

Recent publications

Preoperative Glycosylated Hemoglobin A1C Impacts Long‐Term Outcomes Following Curative‐Intent Resection of Nonfunctional Gastroenteropancreatic Neuroendocrine Tumors
Journal of Surgical Oncology 2024cited by 0position: middledoi
Surgical outcomes of gastro‐entero‐pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma
Journal of Surgical Oncology 2022cited by 9position: middledoi
Recurrence of Non‐functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burden‐Based Prediction Model
World Journal of Surgery 2021cited by 15position: middledoi
Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit
Journal of Surgical Oncology 2020cited by 34position: middledoi
Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors
HPB 2020cited by 33position: middledoi
Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group
Neuroendocrinology 2020cited by 26position: middledoi
Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy
Journal of Surgical Oncology 2020cited by 3position: middledoi
A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors
Annals of Surgery 2019cited by 80position: middledoi
New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors
Annals of Surgery 2019cited by 61position: middledoi
Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group
Annals of Surgical Oncology 2019cited by 44position: firstdoi
The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management
Surgery 2019cited by 44position: firstdoi
Association of preoperative monocyte‐to‐lymphocyte and neutrophil‐to‐lymphocyte ratio with recurrence‐free and overall survival after resection of pancreatic neuroendocrine tumors (US‐NETSG)
Journal of Surgical Oncology 2019cited by 44position: middledoi
Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group
Journal of Surgical Oncology 2019cited by 37position: middledoi
Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium
Annals of Surgical Oncology 2019cited by 30position: firstdoi
Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis
Annals of Surgical Oncology 2019cited by 29position: middledoi
Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence
HPB 2019cited by 28position: middledoi
Caution: Increased Acute Kidney Injury in Enhanced Recovery after Surgery (ERAS) Protocols
The American Surgeon 2019cited by 25position: middledoi
Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection
HPB 2019cited by 24position: middledoi
Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors
JAMA Surgery 2018cited by 80position: middledoi
Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group
Surgery 2018cited by 55position: middledoi
Nomogram predicting the risk of recurrence after curative‐intent resection of primary non‐metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group
Journal of Surgical Oncology 2018cited by 45position: middledoi
Does Surgical Margin Impact Recurrence in Noninvasive Intraductal Papillary Mucinous Neoplasms?
Annals of Surgery 2018cited by 32position: middledoi
Transplantation Versus Resection for Hilar Cholangiocarcinoma
Annals of Surgery 2017cited by 186position: middledoi
Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium
The American Surgeon 2017cited by 79position: middledoi
Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease
HPB 2017cited by 49position: middledoi
Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium
Journal of the American College of Surgeons 2016cited by 40position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Shishir K. Maithel · Robert H. Lurie Comprehensive Cancer Center of Northwestern University24 papers (2016–2024)George A. Poultsides · Stanford University22 papers (2016–2024)Kamran Idrees · Vanderbilt University22 papers (2016–2024)Ryan C. Fields · University of Missouri–St. Louis22 papers (2016–2024)Flavio G. Rocha · Virginia Mason Medical Center17 papers (2018–2022)Sharon M. Weber · Northwell Health17 papers (2016–2024)Paula Marincola Smith · The Ohio State University Wexner Medical Center12 papers (2018–2020)Bradley A. Krasnick · New York University12 papers (2017–2020)Mary Dillhoff · The Ohio State University11 papers (2018–2020)Megan Beems · University of Michigan–Ann Arbor11 papers (2018–2020)Cliff Cho · University of Michigan–Ann Arbor11 papers (2018–2024)Zaheer Kanji · The Ohio State University Wexner Medical Center10 papers (2018–2020)Eleftherios Makris · University of California, Davis10 papers (2018–2020) · 9 papers (2018–2020)Timothy M. Pawlik · University of Tampa9 papers (2017–2024)Xu‐Feng Zhang · The Ohio State University Wexner Medical Center9 papers (2018–2024)Timothy M. Pawlik · Columbus Oncology and Hematology Associates8 papers (2016–2020)Carl Schmidt · West Virginia University7 papers (2016–2019)Daniel E. Abbott · Medical College of Wisconsin7 papers (2016–2020)Eliza W. Beal · The Barbara Ann Karmanos Cancer Institute6 papers (2017–2020)